Clinical Trial Update: Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase [Phase 2]

View source ↗

Summary

This document describes a Phase II clinical trial evaluating dasatinib in combination with ropeginterferon alfa-2b for newly diagnosed chronic myeloid leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Ropeginterferon alfa-2b (ropeginterferon alfa-2b)
• Sprycel (dasatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: NOT_YET_RECRUITING